Beigene (NASDAQ:ONC) Earns Outperform Rating from Royal Bank of Canada

Beigene (NASDAQ:ONC)‘s stock had its “outperform” rating restated by Royal Bank of Canada in a research note issued to investors on Monday,Benzinga reports. They currently have a $312.00 price objective on the stock. Royal Bank of Canada’s price objective points to a potential upside of 24.91% from the stock’s previous close.

Other analysts have also issued research reports about the company. Guggenheim reissued a “buy” rating on shares of Beigene in a research report on Wednesday, April 16th. JMP Securities set a $348.00 target price on Beigene in a research note on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and lifted their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. JPMorgan Chase & Co. increased their price target on shares of Beigene from $311.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, April 21st. Finally, TD Securities reissued a “buy” rating and issued a $334.00 price objective on shares of Beigene in a research note on Thursday, April 24th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $318.88.

Beigene Stock Up 0.1 %

ONC stock opened at $249.77 on Monday. Beigene has a 52-week low of $141.31 and a 52-week high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The firm has a market capitalization of $24.69 billion, a PE ratio of -30.31, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49. The stock’s fifty day simple moving average is $248.20.

Beigene (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, sell-side analysts anticipate that Beigene will post -5.82 EPS for the current year.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker sold 732,827 shares of the company’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the completion of the transaction, the director now directly owns 730,642 shares of the company’s stock, valued at approximately $189,966,920. This represents a 50.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Xiaodong Wang sold 41,760 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $242.66, for a total value of $10,133,481.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,146,048 shares of company stock worth $295,198,300. Company insiders own 6.62% of the company’s stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.